AQX-435

• CAT Number: I022364
• CAS Number: 1619983-52-6
• Molecular Formula: C27H34N2O4
• Molecular Weight: 450.57
• Purity: ≥95%
• Synonyms: N-[(2R,3S,4S,4aS,8aS)-4-(3,5-dihydroxybenzoyl)-3,4a,8,8-tetramethyl-1,2,3,4,5,6,7,8a-octahydronaphthalen-2-yl]pyridine-3-carboxamide
• InChI: InChI=1S/C27H34N2O4/c1-16-21(29-25(33)17-7-5-10-28-15-17)14-22-26(2,3)8-6-9-27(22,4)23(16)24(32)18-11-19(30)13-20(31)12-18/h5,7,10-13,15-16,21-23,30-31H,6,8-9,14H2,1-4H3,(H,29,33)/t16-,21-,22+,23-,27+/m1/s1
• InChIKey: JBBCDNNDYGLMOE-LZITZJIASA-N
• SMILES: C[C@@H]1[C@@H](C[C@@H]2[C@@]([C@H]1C(=O)C3=CC(=CC(=C3)O)O)(CCCC2(C)C)C)NC(=O)C4=CN=CC=C4

AQX-435（Cat No.:I022364）is a potent and selective small-molecule inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), an isoform predominantly expressed in leukocytes and critical for B-cell receptor signaling. By inhibiting PI3Kδ, AQX-435 disrupts downstream pathways involved in cell survival, proliferation, and immune regulation. It has shown promise in preclinical models of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). AQX-435 may also enhance the efficacy of monoclonal antibody therapies by sensitizing cancer cells to immune-mediated killing, offering potential for combination strategies in targeted cancer treatment.